Sunday, June 5, 2016

Allergy Therapeutics (LON:AGY) boss excited by PQBirch204 Phase II data: ProactiveInvestors Stocktube

Published on 9 May 2016
Manuel Llobet, chief executive of Allergy Therapeutics plc (LON:AGY) says the latest data from its Phase II trial of its PQBirch204 treatment for hay fever caused by birch pollen is “exciting for our company”.

Allergy released the results from the latest clinical study, which assessed the response from 371 patients.
The phase II trial revealed a statistically significant dose-response relationship from the groups receiving the medication, with Llobet noting the company has received “very strong top –line data”.
It means the company is still on track to start the Phase III study in early 2017, and Llobet 
says the data is “another step towards our clinical goal to get Polinex Quattro Birch registered in Europe as soon as possible”.

Allergy Therapeutics
Welcome to Allergy Therapeutics, a European-based pharmaceutical company dedicated to continued allergy prevention.

No comments: